Research Article
Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy
Table 1
Baseline characteristics and responses to treatment for all subjects grouped according to anti-PLA2R status after 6-month therapy.
| | Total | Group 1 (anti-PLA2R positive; clearance at 6 months) | Group 2 (anti-PLA2R positive; persistence at 6 months) | Group 3 (anti-PLA2R negative) | |
| | Baseline characteristics | | | | | (Among groups) | | Number | 73 | 29 | 22 | 22 | | | Age (years) | | | | | 0.089 | | Gender (M/F) | 49/24 | 24/5 | 13/9 | 12/10 | 0.142 | | Serum creatinine (mg/dL) | | | | | 0.891# | | Creatinine clearance (mL/min per 1.73 m2) | | | | | 0.183 | | Serum albumin (g/dL) | | | | | 0.893 | | Baseline proteinuria (g/day) | | | | | 0.804 | | Responses to treatment | | | | | (Group 1 vs. 2) | | Baseline anti-PLA2R (RU/mL) | | | | — | <0.001 | | 6-month anti-PLA2R (RU/mL) | | | | — | <0.001 | | 12-month anti-PLA2R (RU/mL) | | | | — | | | 24-month anti-PLA2R (RU/mL) | | | | — | | | 6-month outcome (CR/PR vs. LR/NR) | 45 vs. 28 | 24 vs. 5 | 9 vs. 13 | 12 vs. 10 | 0.005 | | 12-month outcome (CR/PR vs. LR/NR) | 51 vs. 22 | 27 vs. 2 | 10 vs. 12 | 14 vs. 8 | <0.001 | | 24-month outcome (CR/PR vs. LR/NR) | 58 vs. 13 | 28 vs. 1 | 13 vs. 9 | 17 vs. 3 | <0.001 |
|
|
Summary data are presented as . M: male; F: female; CR: complete remission; LR: limited response; NR: nonresponder; PR: partial remission. #Normal distribution; nonnormal distribution. |
